In vitro efficacy of L-asparaginase in childhood acute myeloid leukaemia

British Journal of Haematology

Volumn 123, Issue 5, 2003, Pages 802-809

  Okada, Shuichi ^a   Hongo, Teruaki ^a   Yamada, Sayuri ^a   Watanabe, Chieko ^a   Fujii, Yuji ^a   Ohzeki, Takehiko ^a   Horikoshi, Yasuo ^b   Ito, Tsuyoshi ^c   Yazaki, Makoto ^d   Komada, Yoshihiro ^e   Tawa, Akio ^f,g  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^c TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^d Department of Paediatrics   (Japan)

^e MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OSAKA NATIONAL HOSPITAL   (Japan)

^g AML Committee   (Germany)

Author keywords

Acute myeloid leukaemia; Childhood leukaemia; French American British subtypes; L asparaginase; Methyl thiazol tetrazolium assay

Indexed keywords

ASPARAGINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFANT; LETHAL DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ACUTE DISEASE; ADOLESCENT; AGE FACTORS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFANT; LETHAL DOSE 50; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LYMPHOCYTE COUNT; MALE; SEX FACTORS;

EID: 10744219546     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04703.x     Document Type: Article

References (33)

1. Ahlke, E., Nowak-Göttl, U., Schulze-Westhoff, P., Werber, G., Börste, H., Würthwein, G., Jürgens, H. & Boos. J. (1997) Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. British Journal of Haematology, 96, 675-681.
2. Aslanian, A.M. & Kilberg, M.S. (2001) Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochemical Journal, 358, 59-67.
3. Asselin, B.L., Kreissman, S., Coppola, D.J., Bernal, S.D., Leavitt, P.R., Gelber, R.D., Sallan, S.E. & Cohen, H.J. (1999) Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology, 21, 6-12.
4. Athale, U.H., Razzouk, B.I., Raimondi, S.C., Tong, X., Behm, F.G., Head, D.R., Rubnitz, J.E., Bowman, L., Strivastava, D.K., Rubnitz, J.E., Pui, C.H. & Ribeiro, R.C. (2001) Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood, 97, 3727-3732.
5. Avvisati, G., Petti, M.C., Lo-Coco, F., Vegna, M.L., Amadori, S., Baccarani, M., Cantore, N., Di Bona, E., Ferrara, F., Fioritoni, G., Gallo, E., Invernizzi, R., Lazzarino, M., Liso, V., Mariani, G., Ricciuti, F., Selleri, C., Sica, S., Veneri, D. & Mandelli, F. (2002) Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood, 100, 3141-3146.
6. Béné, M.C., Bernier, M., Casasnovas, R.O., Castoldi, G., Doekharan, D., van der Holt, B., Knapp, W., Lemež, P., Ludwig, W.D., Matutes, E., Orfao, A., Schoch, C., Sperling, C. & van't Veer, M.B. (2001) Acute myeloid leukaemia MO: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. British Journal of Haematology, 113, 737-745.
7. Bussolati, O., Belletti, S., Uggeri, J., Gatti, R., Orlandini, G., Dal-l'Asta, V. & Gazzola, G.C. (1995) Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells. Experimental Cell Research, 220, 283-291.
8. Chakrabarti, R. & Schuster, S.M. (1997) L-asparaginase - perspectives on the mechanisms of action and resistance. International Journal of Pediatric Hematology/Oncology, 4, 597-611.
9. Clarkson, B., Krakoff, I., Burchenal, J., Karnofsky, D., Golbey, R., Dowling, M., Oettgen, H. & Lipton, A. (1970) Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer, 25, 279-305.
10. Codegoni, A.M., Biondi, A., Conter, V., Masera, G., Rambaldi, A. & D'Incalci, M. (1995) Human monocytic leukemia expresses low levels of asparagine synthase and is potentially sensitive to L-asparaginase. Leukemia, 9, 360-361.
11. Dübbers, A., Würthwein, G., Müller, H.J., Schulze-Westhoff, P., Winkelhorst, M., Kurzknabe, E., Lanvers, C., Pieters, R., Kaspers, G.J.L., Creutzig, U., Ritter, J. & Boos, J. (2000) Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity. British Journal of Haematology, 109, 427-429.
12. Estlin, E.J., Ronghe, M., Burke, G.A.A. & Yule, S.M. (2000) The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia. British Journal of Haematology, 110, 780-790.
13. Fumarola, C., Zerbini, A. & Guidotti, G.G. (2001) Glutamine deprivation-mediated cell shrinkage induces ligand-independent CD95 receptor signaling and apoptosis. Cell Death and Differentiation, 8, 1004-1013.
14. Hongo, T., Yajima, S., Sakurai, M., Horikoshi, Y. & Hanada, R. (1997) In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood, 89, 2959-2965.
15. Hongo, T., Yamada, S., Yajima, S., Watanabe, C., Fujii, Y., Kawasaki, H., Yazaki, M., Hanada, R. & Horikoshi, Y. (1999) Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia. International Journal of Hematology, 70, 268-277.
16. Hongo, T., Okada, S., Inoue, N., Yamada, S., Yajima, S., Watanabe, C., Fujii, Y. & Horikoshi, Y. (2002) Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing. International Journal of Hematology, 76, 251-259.
17. Hutson, R.G., Kitoh, T., Moraga Amador, D.A., Cosic, S., Schuster, S.M. & Kilberg, M.S. (1997) Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. American Journal of Physiology, 272, C1691-C1699.
18. Kaspers, G.J.L., Veerman, A.J.P., Pieters, R., Van Zantwijk, C.H., Smets, L.A., Van Wering, E.R. & Van Der Does-Van Den Berg, A. (1997) In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood, 90, 2723-2729.
19. Kaspers, G.J.L., Zwaan, C.M., Veerman, A.J.P., Rots, M.G., Pieters, R., Bucsky, P., Domula, M., Göbel, U., Graf, N., Havers, W., Jorch, N., Kabisch, K., Spaar, H.J., Ritter, J. & Creutzig, U. (1999) Cellular drug resistance In acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study. Klinische Pädiatrie, 211, 239-244.
20. Kitoh, T., Nishimura, S., Shirahase, H., Usami, I., Kubota, M., Akiyama, Y., Frusho, K. & Shuster, S.M. (1996) Immunocytochemical analysis of asparagine synthetase protein of leukemia cells: indication for L-asparaginase treatment. Blood, 88(Suppl. 1), 86a.
21. Kitoh, T., Sawada, M., Shirahase, H., Hamahata, K., Usami, I., Ying-Wei, L., Akiyama, Y., Kubota, M. & Schuster, S.M. (1998) Asparagine synthetase protein expression in leukemia cells: application of L-asparaginase treatment for leukemia. Blood, 92(Suppl. 1), 400a.
22. Klumper, E., Ossenkoppele, G.J., Pieters, R., Huismans, D.R., Loonen, A.H., Rottier, A., Westra, G. & Veerman, A.J.P. (1996) In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. British Journal of Haematology, 93, 903-910.
23. Müller, H.J. & Boos, J. (1998) Use of L-asparaginase in childhood ALL. Critical Reviews in Oncology/Hematology, 28, 97-113.
24. Ohnuma, T., Holland, J.F., Freeman, A. & Sinks, L.F. (1970) Biochemical and pharmacological studies with asparaginase in man. Cancer Research, 30, 2297-2305.
25. Pieters, R., den Boer, M.L., Durian, M., Janka, G., Schmiegelow, K., Kaspers, G.J.L., van Wering, E.R. & Veerman, A.J.P. (1998) Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - implications for treatment of infants. Leukemia, 12, 1344-1348.
26. Pratt, C.B., Simone, J.V., Zee, P., Aur, R.J.A. & Johnson, W.W. (1970) Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia. Journal of Pediatrics, 77, 474-483.
27. Scherf, U., Ross, D.T., Waltham, M., Smith, L.H., Lee, J.K., Tanabe, L., Kohn, K.W., Reinhold, W.C., Myers, T.G., Andrews, D.T., Scudiero, D.A., Eisen, M.B., Sausville, E.A., Pommier, Y., Botstein, D., Brown, P.O. & Weinstein, J.N. (2000) A gene expression database for the molecular pharmacology of cancer. Nature Genetics, 24, 236-244.
28. + pediatric ALL. Blood, 101, 2743-2747.
29. Vardiman, J.W., Harris, N.L. & Brunning, RD. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 2292-2302.
30. Yamada, S., Hongo, T., Okada, S., Watanabe, C., Fujii, Y. & Ohzeki, T. (2001a) Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia, 15, 1892-1897.
31. Yamada, S., Hongo, T., Okada, S., Watanabe, C., Fujii, Y., Hori, H., Yazaki, M., Hanada, R. & Horikoshi, Y. (2001b) Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome. International Journal of Hematology, 74, 428-436.
32. Zwaan, C.M., Kaspers, G.J.L., Pieters, R., Ramakers-Van Woerden, N.L., den Boer, M.L., Wünsche, R., Rottier, M.M.A., Hählen, K., van Wering, E.R., Janka-Schaub, G.E., Creutzig, U. & Veerman, A.J.P. (2000) Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood, 96, 2879-2886.
33. Zwaan, C.M., Kaspers, G.J.L., Pieters, R., Hählen, K., Huismans, D.R., Zimmermann, M., Harbott, J., Slater, R.M., Creutzig, U. & Veerman, A.J.P. (2002) Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood, 100, 3352-3360.